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ABSTRACT
Pancreatic adenocarcinoma is one of the most leading causes of cancer-related 
deaths worldwide. Although recent advances provide various treatment options, 
pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective 
therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic 
adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic 
adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our 
study found that p70S6K1 plays an important role in gemcitabine chemoresistence. 
MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its 
expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our 
findings revealed a new mechanism underlying gemcitabine chemoresistance in 
pancreatic adenocarcinoma cells.
INTRODUCTION
Pancreatic adenocarcinoma is the fourth leading 
cause of cancer-related death around the world with 
extremely poor prognosis [1]. The five-year survival rate 
for pancreatic adenocarcinoma patients is approximately 
6%, with a median survival of 4-6 months. Thus, 
pancreatic adenocarcinoma is often diagnostic after it is 
well-advanced because of its asymptomatic nature [2]. 
Less than 15% pancreatic adenocarcinoma patients are 
suitable for operation at the time of diagnosis, which means 
chemotherapy has been the major treatment for most of 
the pancreatic adenocarcinoma patients [3]. Gemcitabine 
(2’-deoxy-2’-difluorodeoxycytidine), a nucleoside 
analog, has been confirmed to be the first effective drug in 
pancreatic adenocarcinoma treatment by inhibiting DNA 
synthesis and stimulating apoptosis of cancer cells [4]. 
The gemcitabine-related therapy is the medical treatment 
scanty of clinically effects for pancreatic adenocarcinoma. 
In addition, only less than 20% pancreatic adenocarcinoma 
patients are sensitive to gemcitabine treatment, remaining 
the major challenge for pancreatic adenocarcinoma 
treatments [5]. Thus, it will contribute to the development 
of a novel therapeutic strategy to explore the mechanisms 
underlying gemcitabine resistance and enhance the 
efficacy of gemcitabine in pancreatic adenocarcinoma 
treatment [6].
P70S6K1, one of the most important downstream 
targets of mTOR, can be activated by the PI3K/PTEN/
AKT signaling pathway and functions as a key regulator 
in various cellular functions such as cell cycle, cell 
apoptosis and chemoresisitence [7]. Given the significant 
role of p70S6K1 in cellular functions, p70S6K1 is proven 
to be the multifunctional hallmark in cancer therapy [8]. 
In addition, recent studies demonstrated that p70S6K1 is 
involved in nucleotide synthesis via regulating enzymatic 
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activities of carbamoyl phosphate synthetase 2 (CAD) 
[9, 10], indicating the potential role of p70S6K1 in 
gemcitabine action.
MicroRNAs are small non-coding regulatory 
RNAs that have been confirmed to participate in human 
tumorigenesis by directly targeting tumor related genes 
[11, 12]. Recent studies in pancreatic adenocarcinoma 
show indispensable roles of miRNAs in various cellular 
functions, for example, miRNA-21, miRNA-33a, 
miRNA-155 and miRNA-218 exhibit important roles in 
tumor proliferation, invasion, metastasis, and apoptosis 
[13]. However, only a few miRNAs were identified to 
be involved in gemcitabine chemoresistence, such as 
miR-21, miR-181b and miR-17-92 cluster [14–16]. 
MiRNA-145 has been known as a tumor suppressor which 
is frequently downregulated in various types of cancer 
including breast cancer [17], colon cancer [18], prostate 
cancer [19], bladder cancer [20], and osteosarcomas [21]. 
Although some studies indicate the oncogenic potential 
of miR-145 in SW620 cells showing increasing cell 
proliferation/metabolic activity, miRNA-145 participates 
in cancer development mostly by targeting significant 
oncogenes and effectively suppressing their expression 
in different signal pathways, thus inhibiting cancer cell 
proliferation, invasion and metastasis or enhancing 
chemosensitivity [22, 23]. Characterization of global 
microRNA expression reveals anticancer potential of miR-
145 in metastatic colorectal cancer. Early evidence from 
our lab demonstrated that miR-145 negatively regulated 
p70S6K1 expression at the posttranscriptional level in 
colon cancer [18]. Here we demonstrate that miR-145 
increases sensitivity of pancreatic adenocarcinoma cells 
to gemcitabine treatment, providing new insights into 
the role of miR-145/P70S6K1 in mediating gemcitabine 
chemosensitivity.
RESULTS
Gemcitabine treatment induces miR-145 up-
regulation in pancreatic adenocarcinoma cells
To identify miRNAs whose expression levels were 
altered in pancreatic cells in response to gemcitabine 
treatment, we used CCK8 assay to test the effective 
concentrations of gemcitabine treatment in Bxpc-3 and 
Panc-1 cells, and found out that Bxpc-3 was sensitive, 
whereas Panc-1 was resistant to gemcitabine treatment, 
with more than 100-fold higher IC50 in Panc-1 cells 
(Figure 1A and 1B). After determining the appropriate 
gemcitabine concentrations in these cell lines, we treated 
Bxpc-3 cells with gemcitabine (2.5 μM) or vehicle control, 
and quantified miRNA expression profile by using qRT-
PCR analysis. We observed that miR-145 was the most 
significantly up-regulated miRNA upon treatment (Figure 
1C), thus we selected miR-145 as a candidate miRNA 
in tumor progression and chemotherapy for further 
study. When Bxpc-3 and Panc-1 cells were exposed 
to gemcitabine treatment at different concentrations, 
expression levels of miR-145 were increased in a dose-
dependent manner in Bxpc-3 cells, whereas there was no 
significant change on miR-145 expression in Panc-1 cells 
(Figure 1D and 1E), suggesting that miR-145 expression 
was substantially up-regulated by gemcitabine treatment 
in gemcitabine-sensitive cells and the block of miR-145 
enhancement in gemcitabine-resistant cells may be a 
potential mechanism for gemcitabine chemoresistance.
MiR-145 is involved in cell migration and 
gemcitabine chemosensitivity in pancreatic 
adenocarcinoma cells
Stable cell lines over-expressing miR-145 or 
negative control miRNA (miR-NC) were established using 
lentivirus carrying miR-145 or miR-NC, and verified by 
detecting the expression of miR-145 levels in Bxpc-3 and 
Panc-1 cells (Figure 2A). One of the key characteristics 
of malignant tumor is migration, we next investigated the 
effects of miR-145 over-expression on migration in vitro. 
Forced expression of miR-145 dramatically inhibited 65% 
and 50% cell migration capacity of Bxpc-3 and Panc-1 
cells, respectively (Figure 2B and 2C). The miR-145-
overexpressing pancreatic adenocarcinoma cells were 
used to analyze cell viability upon gemcitabine treatment. 
The results showed that over-expression of miR-145 in 
pancreatic adenocarcinoma cells significantly increased 
the sensitivity to gemcitabine treatment (Figure 2D and 
2E). To examine the basal levels of miR-145 expression 
in these cell lines, we found that compared with Panc-1, 
Bxpc3 has higher expression levels of miR-145. Therefore, 
we knocked down miR-145 in Bxpc-3 cells to further 
verify the biological function of miR-145. We found that 
miR-145 interference effectively increased the viability 
of Bxpc-3 cells upon gemcitabine treatment (Figure 2F), 
and cell proliferation was enhanced by miR-145 inhibition 
under the treatment of gemcitabine in Bxpc-3 cells (Figure 
2G). Furthermore, Transwell assay showed that miR-145 
interference enhanced the migration of Bxpc-3 cells.
P70S6K1 is a direct target of miR-145
Growing evidence indicates that p70S6K1 pathway 
is involved in cell growth, metastasis and drug resistance. 
Bioinformatics program was used to predict targets of 
miR-145, among which p70S6K1 was one of the putative 
targets of miR-145. Next, we examined whether p70S6K1 
is a direct target of miR-145. The sequences of p70S6K1 
3’-UTR region with miR-145 potential binding site was 
shown in Figure 3A. To verify whether miR-145 directly 
targets p70S6K1, p70S6K1 3′-UTR sequences containing 
putative binding sites of wild type (WT) or the mutant one 
(mut) (Figure 3A) were cloned into pMIR-REPORTER 
vector. HEK293T cells were co-transfected with the wild 
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Figure 1: Gemcitabine treatment induces miR-145 up-regulation in gemcitabine-sensitive pancreatic adenocarcinoma 
cells. A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different 
doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. C. Expression levels of 
miRNAs in Bxpc-3 cells were analyzed by RT-qPCR analysis with the treatment of gemcitabine (2.5 μM) for 48 h. D, E. Expression levels 
of miR-145 in Bxpc-3 (D) and Panc-1 (E) cells treated with different doses of gemcitabine. Data from three independent experiments were 
shown as mean ± SEM. * indicated significant difference at P<0.05. ;** indicated significant difference at P<0.01.
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Figure 2: MiR-145 over-expression attenuates cell migration and enhances gemcitabine chemosensitivity in pancreatic 
adenocarcinoma cells. A. The levels of miR-145 were detected using RT-qPCR in the two cell lines over-expressing miR-145 or miRNA 
negarive control (miR_NC). B, C. Transwell assay was used to measure cell migration in both Bxpc-3 (B) and Panc-1 (C) cells stably 
expressing negative control miRNA (miR-NC) or miR-145 precursor, and the results were normalized to cells expressing miR-NC. D. The 
effects of miR-145 over-expression on cell viability in Bxpc-3 and Panc-1 cells treated with indicated concentrations of gemcitabine were 
analyzed using CCK-8 assay.
(Continued)
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type (WT) or mutant (Mut) p70S6K1 3’-UTR luciferase 
reporter vector together with miR-145 mimics or miR-
NC for 24 h, and luciferase activities in those cells were 
measured. Overexpression of miR-145 significantly 
inhibited the luciferase activities of wild-type, but not 
mutant p70S6K1 3'-UTR reporter in HER293T cells 
(Figure 3B), suggesting that miR-145 targets p70S6K1 
through the binding to the seed sequence of its 3’-UTR. To 
determine whether p70S6K1 was down-regulated under 
gemcitabine treatment, Bxpc-3 cells were treated with 
gemcitabine for 48 h and the protein levels of p70S6K1, 
p-S6, HIF-1α and GAPDH were examined. We found that 
the levels of p70S6K1, p-S6 and HIF-1α were significantly 
suppressed in a dose-dependent manner (Figure 3C). In 
addition, miR-145 over-expression markedly suppressed 
protein expression levels of p70S6K1, p-S6, HIF-
1α and VEGF in pancreatic cancer cells (Figure 3D), 
confirming that miR-145 targets p70S6K1 and inhibits 
relative signaling molecules in these cells. Consistent 
with HIF-1α and VEGF protein down-regulation in miR-
145-overexpressing Bxpc-3 and Panc-1 cells, forced 
expression also suppressed VEGF mRNA levels in these 
cells (Figure 3E). Furthermore, as shown in Figure 3F, 
we measured mRNA levels of miR-145 and p70S6K1 in 
pancreatic adenocarcinoma tumor tissues and determined 
the correlation between p70S6K1 levels and miR-145 
expression levels (Figure 3F). Spearman’s rank correlation 
analysis showed that expression levels of p70S6K1 and 
miR-145 in pancreatic adenocarcinoma specimens were 
inversely correlated (Spearman’s correlation r = -0.5361).
Overexpression of p70S6K1 reverses the 
inhibitory effect of miR-145 on cell migration 
and chemoresistance
To identify potential molecular mechanism of 
miR-145 in pancreatic adenocarcinoma development 
and treatment resistance, we determined whether 
miR-145 inhibited cell migration and cell viability 
under gemcitabine treatment though p70S6K1. The 
ove-rexpression of miR-145 decreased endogenous 
p70S6K1 protein levels, whereas forced expression 
of p70S6K1 without 3’-UTR dramatically increased 
p70S6K1 expression levels (Figure 4A). Over-expression 
of p70S6K1 rescued the ability of cell migration 
which was suppressed by miR-145 over-expression in 
pancreatic adenocarcinoma cell lines (Figure 4B and 
4C). Furthermore, cell growth rate in the presence of 
gemcitabine was assayed by CCK-8 proliferation assay 
at different time points. Our results showed that the 
restoration of p70S6K1 expression in the cells stably over-
expressing miR-145 significantly increased gemcitabine 
chemoresistance (Figure 4D). To further study whether 
p70S6K1 is required for gemcitabine-resistance in 
pancreatic cancer cells, we confirmed that knockdown 
of p70S6K1 using its shRNA significantly increased cell 
Figure 2 (Continued): E. The endogenous expression levels of miR-145 in Bxpc-3 and Panc-1 cells. F. Bxpc-3 and Panc-1 transfected 
with miR-145 inhibitor (Anti-miR-145) or the negative control miRNA inhibitor (miR-NC) were treated with different concentration of 
gemcitabine for 48 h. The cell viability was analyzed using CCK-8 assay. G. CCK-8 assay was used to analyze the cell viability of Bxpc-3 
cells transfected with miR-145 inhibitor or miR-NC for 48h at indicated time points. H. Cell migration of Bxpc-3 cells transfected with 
miR-145 inhibitor. Data represent mean ± SEM from 3 replicates. * indicated significant difference at P<0.05;** indicated significant 
difference at P<0.01.
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Figure 3: P70S6K1 is a direct target of miR-145. A. Schematic diagram of putative miR-145 binding site in the 3′-UTR region 
of p70S6K1 in human. The seed sequence of miR-145 matches 3’-UTR regions of p70S6K1 (in bold). The mutated nucleotides of the 
p70S6K1 3’-UTR were labeled in red. B. HEK-293T cells were co-transfected with control (miR-NC) or pre-miR-145 mimics along with 
WT or mutant p70S6K1 luciferase reporter as indicated. Luciferase activities were measured 24 h post transfection using the dual-luciferase 
reporter assay system. C. Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, 
p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control. D. Cells were transfected with miR-145 or 
miR-NC. After 72 h, the expression levels of p70S6K1, p-S6, HIF-1α and VEGF were determined as above. E. VEGF levels were measured 
by RT-qPCR in cell lines stably over-exoressing miR-NC and miR-145, and normalized to level of GAPDH. F: Spearman′s correlation 
analysis was used to detect the correlation between expression levels of p70S6K1 and miR-145 at mRNA level in human pancreatic tumor 
specimens. Data represent mean ± SEM of three replicates. * indicated significant difference at P<0.05;** indicated significant difference 
at P<0.01.
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Figure 4: Over-expression of p70S6K1 reverses the inhibitory effects of miR-145. A. Bxpc-3 and Panc-1 cells stably expressing 
miR-NC or miR-145 were transfected with p70S6K1 cDNA construct without 3’-UTR or vector control. After 72 h, p70S6K1 and GAPDH 
expression levels were measured using immunoblotting assay as above. B, C. The effects of p70S6K1 forced expression on cell migration 
were analyzed using Transwell assay in Bxpc-3 (B) and Panc-1 (C) cells stably expressing miR-NC or miR-145. D. The cells above were 
treated with indicated concentrations of gemcitabine at different time point, cell proliferation was analyzed using CCK8 Assay Kit and 
normalized to the number of miR-NC group without gemcitabine treatment. E. Bxpc-3 and Panc-1 cells were transduced with lentivirus 
carrying shRNA against p70S6K1 or negative control (shNC) and selected with puromycin. The stable cells were treated with different 
doses of gemcitabine and cell viability was determined as above. Data represent mean ± SEM. of three replicates. *indicates significant 
difference compared to control at P<0.05; #indicates significant difference compared to miR-145 treatment alone at P<0.05.
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viability upon gemcitabine treatment in both cell lines 
(Figure 4E).
MiR-145 inhibits VEGF transcriptional 
activation through targeting p70S6K1 in 
pancreatic adenocarcinoma cells
Previous studies have shown the importance of 
p70S6K1/HIF-1α/VEGF pathway in the regulation of 
angiogenesis and tumor progression. It has been reported 
that HIF-1α activates the expression of VEGF gene by 
binding to the hypoxia response element (HRE) in the 
VEGF promoter region. To determine whether miR-
145 attenuates VEGF transcriptional activation through 
targeting p70S6K1, we analyzed the effect of miR-
145 on the wild type VEGF promoter reporter plasmid 
(pMAP11WT) containing the HIF-1α binding site or the 
mutant plasmid (pMAP11Mut) with or without p70S6K1 
over-expression. As shown in Figure 5A and 5B, forced 
expression of p70S6K1 restored miR-145-inhibited the 
wild type VEGF reporter activity in Bxpc-3 and Panc-
1 cells, but did not affect the mutant reporter activity, 
indicating that miR-145 inhibits VEGF transcriptional 
activation by targeting p70S6K1.
DISCUSSION
Pancreatic adenocarcinoma is one of the most 
common digestive tract malignant tumors, which is 
difficult in early diagnosis and treatment. In present, 
distant metastasis, relapse, and drug resistance are still 
very difficult problems in cancer therapy. Gemcitabine, a 
first-line treatment drug of pancreatic adenocarcinoma, is 
widely used in clinical practice. Currently, some literatures 
suggest that miRNAs can affect drug sensitivity of tumor 
cells to gemcitabine treatment, including miR-218, miR-
33a and miR-223 [24–26], but the role and molecular 
mechanism of miRNAs in pancreatic adenocarcinoma cells 
to gemcitabine treatment have not been reported. We found 
that compared with Bxpc-3, a much higher concentration 
of gemcitabine was required to inhibit the cell viability of 
Panc-1, confirming that Panc-1 is a gemcitabine-resistant 
cell line. We also found that gemcitabine could up-regulate 
expression levels of miR-145 in Bxpc-3, the gemcitabine-
sensitive cells, but not in Panc-1 cells, suggesting specific 
role of miR-145 in gemcitabine chemosensitivity in 
pancreatic adenocarcinoma cells.
MiR-145 is known as a tumor suppressor, which 
plays an important role in tumor development. The 
expression levels of miR-145 are found to be down-
regulated in many types of cancers, including pancreatic 
adenocarcinoma [27–31]. The expression profiles and 
biological role of miR-145 in pancreatic adenocarcinoma 
has been reported [31, 32], but the role and mechanisms 
of miR-145 in regulating drug resistance remain to 
be elucidated. In this study, we found that in both 
gemcitabine-sensitive cells Bxpc-3 and gemcitabine-
resistant cells Panc-1, overexpression of miR-145 
significantly inhibited cell migration by directly targeting 
p70S6K1. Moreover, overexpression of miR-145 
increased chemosensitivity of cancer cells to gemcitabine 
treatment in vitro, indicated by decreased cell viability. 
Furthermore, p70S6K1 is a direct target of miR-145 in 
pancreatic cancer cells. Forced expression of p70S6K1 
Figure 5: MiR-145 inhibits VEGF transcriptional activation through targeting p70S6K1 in pancreatic adenocarcinoma 
cells. A. Bxpc-3 cells were co-transfected with wild-type VEGF reporter (pMAP11-WT) or mutant VEGF reporter (pMAP11-mut), miR-
NC negative control or miR-145 precursor, p70S6K1 cDNA or vector control, and pRL-TK plasmid. The luciferase activities were measured 
using firefly and Renilla dual luciferase reporter assay, and normalized to those of the control. B. The similar experiment was performed 
using PANC-1 cells. Data represent mean ± SEM. from three replicates. * indicated significant difference at P<0.05.
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reversed miR-145-suprressed cell proliferation and drug 
resistance of pancreatic adenocarcinoma cells, suggesting 
that p70S6K1 plays a central role in miR-145-induced 
chemosentivity to gemcitabine treatment. MiR-143 may 
have similar effect and regulation mechanism as miR-145 
in cells, which would also be interesting to be studied in 
the future.
The activation of p70S6K1 affects the expression 
levels of two important angiogenesis-related downstream 
signaling molecules, HIF-1α and VEGF, which are 
involved in tumorigenesis and cancer development [33–
37]. It has also been demonstrated that HIF-1α regulates 
VEGF expression at the transcriptional level by binding to 
its promoter [38]. In our study, overexpression of miR-145 
suppressed the expression levels of HIF-1α and VEGF, 
which is consistent with its inhibitory effect on p70S6K1. 
Furthermore, forced expression of p70S6K1 in miR-145-
over-expressing pancreatic adenocarcinoma cells restored 
the expression levels of HIF-1α and VEGF which were 
inhibited by miR-145, suggesting that miR-145 controls 
expression of HIF-1a and VEGF by targeting p70S6K1 
in the cells.
In summary, our findings showed that Panc-1 
resistance to gemcitabine is due to the down-regulation 
of miR-145, suggesting that miR-145 may be an indicator 
for the development of pancreatic adenocarcinoma. 
Forced expression of miR-145 inhibited the cell viability, 
migration, HIF-1α, VEGF expression and enhanced 
the chemosensitivity to gemcitabine through its direct 
target p70S6K1 in pancreatic adenocarcinoma. These 
results suggest that miR-145 may be a potential target 
for adjuvant therapy to enhance the chemosensitivity 
to gemcitabine in the future. Our findings provided a 
new molecular basis for the application of miR-145 in 
pancreatic adenocarcinoma, which may be helpful in 
developing microRNA-based drug for treating pancreatic 
adenocarcinoma in the future.
MATERIALS AND METHODS
Cell culture and reagents
Human pancreatic adenocarcinoma cell lines, Panc-
1 and Bxpc-3 were maintained in Dulbecco's Modified 
Eagle's medium with high glucose and RPMI-1640 
medium with low glucose, respectively, and supplemented 
with 10% fetal bovine serum and antibiotics (100 units/
ml penicillin and 100 mg/ml streptomycin). Cells were 
incubated in a 5% CO2 incubator at 37°C. Trypsin 
(0.25%) solution was used to detach the cells from the 
culture flask. P70S6K1 and VEGF antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Antibodies against HIF-1α and GAPDH were 
purchased from Bioworld Technology (Atlanta, Georgia, 
USA). Gemcitabine was obtained from Sigma (St. Louise, 
MO).
Luciferase reporter assays
The 3’-UTR of p70S6K1 constructs containing 
predicted miR-145 seed-matching sites from cDNA library 
were amplified by PCR using Pfu DNA polymerase, 
then cloned into pMIR-REPORTER vector (Ambion). 
Primers of wide type (WT) and corresponding mutant 
sites (Mut) used for reporter constructions were shown 
in Supplementary Table S1. All the 3’-UTR products 
were sequenced and verified. For reporter assays, HEK-
293T cells were transiently cotransfected with WT or 
Mut plasmid, pRL-TK plasmid and miRNA-145 mimics 
(GenePharma, Shanghai, China) or miRNA-negative 
control (miR-NC) using lipofectamine 2000 (Invitrogen). 
Firefly and renilla luciferase activities were measured 
24 h after transfection using a dual luciferase assay kit 
(Promega, Shanghai, China). The relative luciferase 
activities were calculated and normalized to the control.
To detect the effects of miR-145 on transcriptional 
activation of VEGF, the downstream of p70S6K1, VEGF 
reporter plasmid pMAP11-WT or pMAP11-Mut was co-
transfected into Bxpc-3 and Panc-1 cells with pRL-TK 
plasmid and miR-145 mimics or miR-NC. Firefly and 
Renilla luciferase activities were measured 24 h after 
the transfection. Experiments were performed in three 
independent replicates.
RNA extractions, reverse transcription PCR and 
quantitative real time- PCR
Total RNAs were extracted from cells with TRIzol 
(Invitrogen, CA, USA). The stem-loop RT-PCR assay was 
performed to quantify the miRNAs expression levels using 
the HiScript RT Reagent Kit (Vazyme Biotech, Nanjing, 
China) according to the manufacturer’s instructions. 
To determine the mRNA levels of VEGF, total RNAs 
were reversely transcribed using HiScript RT Reagent 
Kit (Vazyme Biotech, Nanjing, China). RT-qPCR was 
performed to detect mRNA expression levels using the 
SYBR Premix DimerEraser (Takara, Dalian, China) on a 
7900HT system. The expression levels of U6 or GAPDH 
were used as internal control. The expression levels 
of miRNAs in each group were calculated by relative 
quantification (2-ΔΔCt). The primers used in this study are 
shown in Supplementary Table S1.
Cell proliferation
To detect the gemcitabine effects on the pancreatic 
adenocarcinoma cell viablility, cells were seeded into 
96-well plates at 2000 per well. After cellular adhesion, 
medium containing gemcitabine at different concentrations 
was added to the cells. Cell viability was assessed using 
the CCK8 Assay (CCK8 kit, Dojindo Laboratories, 
Kumamoto, Japan) 48 h after the transfection. CCK8 
reagents were prepared in fresh medium (100 μl medium 
containing 10 μl CCK8 solutions) and applied to the cells. 
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The absorbance at 450 nm for each well was analyzed on 
a spectrophotometer.
To determine the effects of miR-145 on cell growth, 
Bxpc-3 and Panc-1 cells were seeded in a 6-well plate and 
cultured overnight. After transient transfection with miR-
145 and miR-NC precursors, the cells were trypsinized 
and seeded into a 96-well plate. CCK8 Assay was used 
to measure cell proliferation at different indicated time 
points.
Cell migration assay
Transwell chambers (24-well insert; Corning, NY, 
USA) were used to analyze cell migration in accordance 
with the manufacturer’s instructions. Cells were seeded in 
the upper well of the chamber in DMEM or RPMI-1640 
medium without serum, while the lower chamber well 
contained DMEM or RPMI-1640 medium supplemented 
with 10% FBS to stimulate cell migration. After 
incubation for 12 h, cells on the upper membrane surface 
were removed while the bottom cells were fixed with 
3% paraformaldehyde, stained with 0.1% crystal violet, 
and 5-6 random fields were collected for quantification 
for each well. The cells were finally extracted with 33% 
acetic acid and detected quantitatively using a standard 
microplate reader (at 570 nm). Three independent 
experiments were performed for each experimental group.
Establishment of stable cell lines expressing 
miR-145
Lentivirus carrying miR-145 and miR-NC were 
packaged using lentiviral packaging kit in HEK-293T 
cells according to the manufacturer’s instructions (Open 
Biosystems, AL, USA). Stable Bxpc-3 and Panc-1 cells 
over-expressing miR-145 or miR-NC were generated by 
the infection of lentivirus (Open Biosystems), followed by 
puromycin (Life Technologies) selection.
Western blotting
Cells were lysed with RIPA buffer (150 mM NaCl, 
100 mM Tris, pH 8.0, 0.1% SDS, 1% Triton X-100, 
1% sodium deoxycholate, 5 mM EDTA, and 10 mM 
NaF) supplemented with 1 mM sodium vanadate, 2 mM 
leupeptin, 2 mM aprotinin, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM DTT, and 2 mM pepstatin. 
Total proteins were collected by centrifugation at 
12,000 rpm 4°C for 15 min. After quantification, 20 
μg protein lysates were separated by SDS–PAGE 
and subsequently transferred to polyvinylidene 
difluoride membranes (Millipore, Billerica, MA, USA), 
membranes were blocked with 5% nonfat dry milk 
for 2 h and incubated with primary antibodies. Protein 
bands were detected by incubation with horseradish 
peroxidase-conjugated antibodies and visualized with 
an electrochemiluminescence detection system (Thermo 
Scientific).
Statistical analysis
Values were obtained from at least three independent 
experiments and presented as means ± SEM. Comparison 
between two groups was conducted using the t-test, 
while comparisons between multiple groups of data were 
performed using analysis of variance (ANOVA). It was 
considered to be statistically significant at P<0.05.
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